Otsuka Holdings Co., Ltd. (OTSKF)
| Market Cap | 40.62B +41.8% |
| Revenue (ttm) | 16.12B +9.1% |
| Net Income | 2.49B -0.9% |
| EPS | 4.73 +0.7% |
| Shares Out | n/a |
| PE Ratio | 16.29 |
| Forward PE | n/a |
| Dividend | 0.63 (0.83%) |
| Ex-Dividend Date | Dec 29, 2026 |
| Volume | 100 |
| Open | 76.10 |
| Previous Close | 76.10 |
| Day's Range | 76.10 - 76.10 |
| 52-Week Range | 54.26 - 79.00 |
| Beta | -0.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Otsuka Holdings
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement... [Read more]
Financial Performance
In 2025, Otsuka Holdings's revenue was 2.47 trillion, an increase of 5.97% compared to the previous year's 2.33 trillion. Earnings were 363.15 billion, an increase of 5.84%.
Financial numbers in JPY Financial StatementsNews
Otsuka Holdings Slides: Q2 2026
Otsuka Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 31, 2026.
Otsuka Holdings Quarterly report: Q2 2026
Otsuka Holdings has published its Q2 2026 quarterly earnings report on July 31, 2026.
Otsuka says kidney disease drug preserves function in late-stage study
Otsuka Pharmaceutical said on Thursday its drug in a late-stage study preserved kidney function over 12 months in patients with a type of autoimmune disease that affects the organ.
Otsuka Holdings Quarterly report: Q1 2026
Otsuka Holdings has published its Q1 2026 quarterly earnings report on April 28, 2026.
Otsuka Holdings Slides: Q1 2026
Otsuka Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Otsuka Holdings Transcript: M&A announcement
The acquisition brings a late-stage PTSD treatment, TSND-201, into the portfolio for $700M upfront plus up to $525M in milestones. The deal leverages existing CNS expertise and targets a large unmet need, with U.S. launch aimed for 2030.
Otsuka Holdings Slides: M&A announcement
Otsuka Holdings has posted slides in relation to its latest quarterly earnings report, which was published on April 9, 2026.
Otsuka Holdings Earnings Call Transcript: Q4 2025
Record revenue and profit highs were achieved in FY 2025, driven by robust pharma and NC business growth. Despite expected profit decline in FY 2026 due to generic competition, strong product launches and strategic investments position the company for sustainable long-term growth.
Otsuka Holdings Quarterly report: Q4 2025
Otsuka Holdings has published its Q4 2025 quarterly earnings report on February 12, 2026.
Otsuka Holdings Slides: Q4 2025
Otsuka Holdings has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Otsuka upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Otsuka (OTSKY) to Overweight from Equal Weight with a price target of 12,600 yen, up from 9,000 yen. The stock currently prices in peak sales of Voyxact…
US FDA approves Otsuka's kidney disease drug
The U.S. Food and Drug Administration has approved Otsuka's injectable drug to treat patients with a potentially life-threatening kidney disease, the health regulator's website showed on Tuesday.
Otsuka Holdings Quarterly report: Q3 2025
Otsuka Holdings has published its Q3 2025 quarterly earnings report on October 31, 2025.
Otsuka Holdings Slides: Q3 2025
Otsuka Holdings has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 31, 2025.
Shares of Asian drugmakers drop after Trump threatens tariffs
Shares of Asian drugmakers mostly fell on Friday after U.S. President Donald Trump threatened 100% tariffs on imports of branded pharmaceuticals from October 1, unless their producers had already brok...
Otsuka Holdings Earnings Call Transcript: Q2 2025
Revenue and profits grew year-over-year in Q2 FY2025, led by strong pharmaceutical and nutraceutical sales. Upward revisions to full-year profit and dividend guidance reflect robust business performance, ongoing pipeline expansion, and enhanced capital efficiency.
Otsuka Holdings Quarterly report: Q2 2025
Otsuka Holdings has published its Q2 2025 quarterly earnings report on July 31, 2025.
Otsuka Holdings Slides: Q2 2025
Otsuka Holdings has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 31, 2025.
Vera Therapeutics drops 30% after rival Otsuka presents Phase 3 data
Shares of Vera Therapeutics (VERA) dropped nearly 30% in premarket trading after rival Otsuka (OTSKY) presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study evaluating ...
Otsuka Holdings Quarterly report: Q1 2025
Otsuka Holdings has published its Q1 2025 quarterly earnings report on April 30, 2025.
Otsuka Holdings Slides: Q1 2025
Otsuka Holdings has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on April 30, 2025.
Otsuka initiated with a Market Perform at Bernstein
Bernstein analyst Miki Sogi initiated coverage of Otsuka (OTSKY) with a Market Perform rating. The firm believes the current stock price appropriately reflects “what is likely to come.” Published firs...
Otsuka downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Chikai Tanaka downgraded Otsuka (OTSKY) to Sell from Neutral with a 3,110 yen price target The company’s strong earnings looks priced into the shares while its fiscal…
Otsuka Holdings Slides: Q4 2024
Otsuka Holdings has posted slides in relation to its Q4 2024 quarterly earnings report, which was published on February 13, 2025.
Otsuka Holdings Quarterly report: Q4 2024
Otsuka Holdings has published its Q4 2024 quarterly earnings report on February 13, 2025.